Peanut allergies is one of the most common allergy worldwide; affecting over 4.2 million children worldwide. This allergy is common due to how it is inhibited by the body. It is created through allergens in peanuts that combine with antibody cells named immunoglobulin E (IgE). This combination creates reactions that shocks the cells of the body causing the symptoms well-known as allergy.
However, a recent study conducted by a team of researchers from the University of Notre Dame were able to develop an inhibitor that can stop peanut allergens from creating this mixture. The results and the study were published in the journal of Proceedings of the National Academy of Sciences and shows a breakthrough for the disease.
The study led by Basar Bilgicer who is an associate professor in the Department of Chemical and Biomolecular Engineering and affiliate of Advanced Diagnostics and Therapeutics at Notre Dame might be the solution for all the affected children who suffer from peanut allergy.
According to Basar, this discovery can actually help cure other diseases who follow the same method of affecting the body. Dr. Basar was excited with their results stating, “The success of this study is exciting because it opens the door to establishing an entirely new class of allergy therapeutics. We now have the first functional example of selective IgE inhibition to a food allergen, which we haven’t had before.”
The study is yet to be tested for further notice and expectation of creating a medicine for children with allergies is yet to be announced.